Protein kinases and phosphatases constitute a large family of conserved enzymes that control a variety of biological processes by regulating the phosphorylation state of target proteins. They play fundamental regulatory roles during cell cycle progression and signaling, among other key aspects of multicellular development. The complement of protein kinases and phosphatases includes approximately 326 members in Drosophila, and they have been the subject of several functional screens searching for novel components of signaling pathways and regulators of cell division and survival. These approaches have been carried out mostly in cell cultures using RNA interference to evaluate the contribution of each protein in different functional assays and have contributed significantly to assign specific roles to the corresponding genes. In this work, we describe the results of an evaluation of the Drosophila complement of kinases and phosphatases using the wing as a system to identify their functional requirements in vivo. We also describe the results of several modifying screens aiming to identify among the set of protein kinases and phosphatases additional components or regulators of the activities of the epidermal growth factor and insulin receptors signaling pathways.
Protein kinases and phosphatases constitute a large family of conserved enzymes that control a variety of biological processes by regulating the phosphorylation state of target proteins. They play fundamental regulatory roles during cell cycle progression and signaling, among other key aspects of multicellular development. The complement of protein kinases and phosphatases includes approximately 326 members in Drosophila, and they have been the subject of several functional screens searching for novel components of signaling pathways and regulators of cell division and survival. These approaches have been carried out mostly in cell cultures using RNA interference to evaluate the contribution of each protein in different functional assays and have contributed significantly to assign specific roles to the corresponding genes. In this work, we describe the results of an evaluation of the Drosophila complement of kinases and phosphatases using the wing as a system to identify their functional requirements in vivo. We also describe the results of several modifying screens aiming to identify among the set of protein kinases and phosphatases additional components or regulators of the activities of the epidermal growth factor and insulin receptors signaling pathways.
Reversible protein phosphorylation was first described in the 1950s (Krebs and Fischer 1955) and since then many studies have emphasized that phosphorylation is one of the main regulatory mechanisms modifying protein activity and consequently a variety of cellular behaviors including cell cycle progression, cell death, metabolism, tissue homeostasis, cell motility, and cell differentiation (Cohen 2001). The phosphorylation state of a protein is a determinant of its biochemical activity and defines protein stability and subcellular location. Protein phosphorylation also allows transitions between active and inactive conformations and influences the repertoire of interactions with other proteins. Not surprisingly, several diseases such as obesity, cancer, and inflammation are related with aberrant phosphorylation, emphasizing its essential role in the regulation of cellular biology (reviewed in Shchemelinin ; Tonks 2006; Hendriks ).The phosphorylation/dephosphorylation of proteins is mediated by protein kinases and protein phosphatases, enzymes that catalyze the transfer of phosphate groups to or from its targets, respectively (Hunter 1995; Shchemelinin ; Hendriks ). Kinases represent one of the largest protein families encoded in eukaryotic genomes, accounting for around 500 genes in humans and 328 genes in Drosophila melanogaster (Morrison ). Phosphatases constitute a smaller group, including about 200 and 192 genes in humans and fly, respectively (Morrison ). There are no Drosophila-specific families of kinases or phosphatases, and each subfamily presents small complexity and low redundancy (Manning ). These characteristics, and the facility of genetic manipulation in this organism, make Drosophila a suitable model for the functional study of these gene families in developing tissues and cell cultures (Mattila ; Read ; Swarup ). One organ that is particularly well suited for such functional approaches is the wing, a flat structure of epidermal origin that has been systematically used as a model system to dissect the molecular components and cell biology underlying epithelial development (Molnar ; Hariharan 2015).The Drosophila wing is a cuticular structure resulting from the differentiation of an epidermal tissue named wing imaginal disc. All features decorating the wing such as sensory organs, pigmentation, and veins are the results of the differentiation, during pupal development, of epidermal cells that were genetically specified during the growth of the wing imaginal disc (Ostalé ). In this manner, wing patterning, as well as its size and shape, is determined during the development of the wing disc. There are multiple cellular processes impinging on wing development that are regulated by the opposing actions of kinases and phosphatases on their targets. These processes include cell growth and division, the acquisition and maintenance of apical-basal and planar polarities and vein differentiation among others (Bettencourt-Dias ; Chen ; Read ; Parsons ). In addition, protein phosphorylation pervades as a regulatory mechanism in multiple signal transduction pathways regulating pattern formation and cell differentiation.One significant advantage of the wing for genetic analysis is the variety and specificity of phenotypic responses to genetic perturbations. For example, altering the activity of signaling pathways results in precise and pathway-specific phenotypes affecting the size and shape of the wing, the formation and polarity of the trichomes differentiated by each epithelial cell, and the position and differentiation of veins (Molnar ; Ostalé ). These phenotypes allow the grouping of novel mutations or knockdown conditions and can be used as a first approximation to assign gene functions by phenotypic comparison. An additional advantage of the wing for genetic analysis is the possibility of carrying out “modifier” screenings using sensitized backgrounds in which the activity of a given signaling pathway is altered. It is expected that sensitized genetic backgrounds help to identify additional components of these pathways or other molecular elements affecting their activities. For example, modifying screens have been instrumental in identifying components of the EGFR and Wnt pathways during imaginal development (Friedman and Perrimon 2006; McElwain ; Swarup ).In this work, we describe the adult wing phenotypes resulting from the individual knockdown of most annotated Drosophila kinases and phosphatases, with particular emphasis in protein kinases and phosphatases. We find that 53% of protein kinases and 40% of protein phosphatases result in mutant wing phenotypes affecting the size, pattern, and differentiation of this organ. This percentage is higher compared to the percentage found for Carbohydrate, Lipid, and Nucleoside kinases (101 genes; 29% knockdowns with a phenotype). In addition, we have constructed and used sensitized genetic backgrounds in which the activities of the epidermal growth factor receptor (EGFR) and insulin receptor (InR) pathways are altered to screen the same collection of protein kinases and phosphatases for genetic interactions.
Materials and methods
Drosophila stocks and genetics
We used the Gal4 lines sal and nub-Gal4. The expression of sal is restricted to the wing blade territory located between the vein L2 and the intervein L4/L5 (Cruz ). The expression of nub-Gal4 is generalized in the entire wing pouch and hinge. For the modifier screens, we used the UAS lines UAS-GFP, UAS-dicer2, UAS-InR (P{UAS-InR.K1409A}; BSCD8252), UAS-InR (P{UAS-InR.R418P}; BSCD8250), UAS-ERK (Brunner ), UAS-ERK-RNAi (VDCR 109108), UAS-EGFR (BDSC59843), and UAS-EGFR-RNAi (VDCR 107130). These lines were combined or recombined with sal. Virgin females of sal, sal, UAS-EGFRλtop; sal, and sal were crossed with males from the collection of UAS-RNAi of the complement of protein kinases and phosphatases. The UAS-RNAi lines used for kinases and phosphatases are listed in Supplementary Table S1. Most UAS-RNAi strains were obtained from the Vienna Drosophila RNAi Center (VDCR; 478 strains), and some from the Bloomington Stock Center (BDSC; 7 strains), and the National Institute of Genetics (NIG-FLY; 6 strains). The knockdown phenotypes of these genes were determined in UAS-dicer2/+; nub-Gal4/UAS-RNAi and UAS-dicer2/+; sal combinations. We aimed to describe each mutant wing using a simplified nomenclature summarizing the main components of its phenotype. Many combinations displayed late larval (LL) or pupal lethality (PL). In many cases, dead pupae observed in the puparium showed necrotic patches in the position normally occupied by the wings (nec). Flies showing a total failure in the formation of the wings were named “nW” (no-wing). Wings showing wing size changes were defined as “S” (wing size smaller than normal) and “S(L)” (wing size larger than normal). When changes in size were accompanied by changes in the pattern of veins, the phenotype was named “S-P.” Changes affecting primarily the wing veins were defined as V− (loss of veins) and V+ (excess of veins). All defects related to the wing margin consisting in the loss of wing margin stretches were defined as “WM.” Defects in the apposition of the dorsal and ventral wing surfaces, observed in the form of blisters, were considered as failures in dorsoventral adhesion, and were named “WA.” Similarly, defects in the global shape of the wing were defined as wing shape (“WS”), and they include lanceolate wings (lan) and dumpy wings (dp). In some cases, the wing cuticle appeared with an abnormal general appearance, brighter than normal, not entirely unfolded or with necrotic patches. These wings were classified as wing differentiation defects (“WD”). In other cases, wing cuticle was darker than normal, and these cases were named “WP” (wing pigmentation defects). Changes in the number of trichomes formed by each cell, which normally differentiate only one trichome, as well as alterations in trichome polarity and spacing, were defined as alterations in cell differentiation (“CD”). A very frequent phenotype observed in combinations between nub-Gal4 and UAS-RNAi strains of the KK VDCR collection result in the formation of adults with the wings totally folded (“WF”). This phenotype is a consequence of a UAS insertion affecting the gene tiptop (Green ; Vissers ). As discussed elsewhere (López-Varea ), the same KK UAS-RNAi lines in combination with the driver sal result in the formation of normal wings, and consequently, all WF wings where we could not observe any other phenotype were considered as wild type for all quantifications. Finally, we included the bins “strong” (s) and weak (w) in the phenotypic description, to give an indication of relative phenotypic strength. Unless otherwise stated, crosses were done at 25°C.We did not measure the efficiency of mRNA knockdown in these genetic combinations. It was estimated in a collection 64 UAS-RNAi/act-Gal4 viable combinations that the reduction in mRNA levels varies from 95% to 10%, and that an estimated 15–40% of UAS-RNAi insertions are inactive (Dietzl ; Perkins ). For these reasons, a fraction of combinations without a mutant phenotype could be due to insufficient knockdown efficiency. In addition, we generally used only one UAS-RNAi strain per gene. However, from our data (López-Varea , G3 submitted), we know that lines targeting the same gene result in similar qualitative phenotypes (202 out of 281 cases analyzed; see López-Varea ) and that in the remaining cases (82% of 79 genes), the more frequent situation is that one nub-Gal4/UAS-RNAi combination results in a mutant phenotype and the other in wild-type flies, again pointing to different knockdown efficiencies between independent strains. In agreement, when we compared our results with a previous RNAi screen of Drosophila protein kinases and phosphatases that used multiple UAS-RNAi lines to target each gene (Swarup ), we found a coincidence for genes showing a wing phenotype in 82% of the genes we identified. The remaining 18% of genes correspond to cases described in Swarup as “mutant wing” where we could not detect a mutant phenotype. These genes are indicated in red lettering in Supplementary Table S1.
Wing and disc measurements
Wing pictures were made with a Spot digital camera coupled to a Zeiss Axioplan microscope, using the 5X and 40X objectives for wings and for wing regions, respectively. Cell size was estimated from the number of trichomes in a dorsal region located between the L2 and L3 longitudinal veins. The number of cells was calculated using cell density and wing size values.
Immunohistochemistry
We used the rabbit antibodies anti-phospho-Histone3 and anti-cleaved Cas3 (Cell Signaling Technology). Alexa Fluor secondary antibodies (used at 1:200 dilution) were from Invitrogen. To stain the nuclei we used TO-PRO-3 (Invitrogen). Imaginal wing discs were dissected, fixed, and stained as described in de Celis (1997). Confocal images were taken in an LSM510 confocal microscope (Zeiss). All images were processed with the program ImageJ 1.45 s (NIH, USA) and Adobe Photoshop CS3.
Statistical analysis
All numerical data including wing size and cell size were collected and processed in Microsoft Excel (Microsoft Inc.). The data and ratios between number of cells were expressed as means + standard error of the mean (SEM) and were compared using a T-test. P-values were adjusted by false discovery rate method using R-studio platform. We consider a significant P-value lower than 0.05 (*), 0.01 (**) and 0.001 (***).
Gene expression
We used RNA-Seq reads from run SRR3478156, corresponding to control larvae expressing Gal4/GFP data obtained from dissected wing imaginal discs (Flegel ) and GeneChip™ Drosophila Genome 2.0 Affymetrix array data (Organista ) to determine expression or not expression in the wing disc for all genes encoding kinases and phosphatases.The authors affirm that all data necessary for confirming the conclusions of the article are present within the article, figures, tables, and Supplementary information.
Results and discussion
Phenotypic screen of kinases in the wing
Kinases catalyze the transfer of a phosphate group from ATP to a substrate molecule. To compile a list of kinases (and phosphatases, see below), we used the classification provided in the FlyBase gene group list (http://flybase.org/lists/FBgg/) and the annotation of protein kinases provided by Morrison . We included in our analysis carbohydrate, lipid, nucleoside, and protein kinases, resulting in a group of 328 genes (Figures 1 and 2A). As a general procedure for the screen, we used only one UAS-RNAi line per gene. We first crossed UAS-RNAi males (Supplementary Table S1) with UAS-dicer2; nub-Gal4/CyO females. In all cases, where the progeny UAS-dicer2/+; nub-Gal4/UAS-RNAi was lethal or resulted in flies with rudimentary wings (42 out of 310 crosses performed), we crossed the corresponding UAS-RNAi lines with UAS-dicer2; sal females. The UAS-dicer2/+ sal combinations were always viable and were used to classify phenotypically the corresponding RNAi lines.
Figure 1
Global parameters of kinases and phosphatases expression and knockdown phenotypes. Summary of the number of genes (TOTAL), genes analyzed (DONE), genes expressed in the wing disc (EXP), genes with a knockdown wing phenotype (PHE), gene knockdowns causing altered wing size (S), and gene knockdowns causing loss of wing or strong defects in wing size and pattern phenotype (S-P/nW).
Figure 2
Global results of the RNAi screen for the complement of Drosophila kinases. (A) Fraction of kinases genes expressed from total (338 genes) and separated into the groups nonprotein kinases (Non-PK) and protein kinases (PK) of the classes AGC Kinases (AGC), Atypical protein kinases (APK), Calcium/Calmodulin-dependent protein kinases (CAMK), CK1 Kinases (CKI), CMGC Kinases (CMGC), other conventional protein kinase domains (OPK), Steryle20 kinases (STE), Tyrosine Kinases (TK), and Tyrosine kinase-like kinases (TLK). (B) Number of genes and percentages of genes with a knockdown mutant phenotype (dark gray sections of each column) or without mutant phenotype (light gray section of each column). Colored sectors show the percentage of each phenotype for nonprotein kinases (left) and for protein kinases (right). Lethality (L; dark blue sector), loss of wing (nW; green sector), changes in wing size and pattern (S-P; light blue sector), changes in size (S; yellow sector), loss of veins (V−; red sector), extra or thicker veins (V+; dark blue sector), wing differentiation defects (WD; orange sector), wing adhesion defects (WA; gray sector), and trichome differentiation or size defects (CD; purple sector). (C) Percentage of lethal and visible mutant phenotypes observed in the AGC, APK, CAMK, CKI, CMGC, OPK, STE, TK, and TKL classes using the same color code as above and indicated below the columns. (D–I) Representative examples of UAS-Dicer2/+; nub-Gal4/UAS-GFP (D), UAS-Dicer2/+; nub-Gal4/UAS-Ret-RNAi (E), UAS-Dicer2/+; nub-Gal4/UAS-gek-RNAi (F), UAS-Dicer2/+; nub-Gal4/UAS-Cdk12-RNAi (G), UAS-Dicer2/+; nub-Gal4/UAS-CKIa-RNAi (H) and UAS-Dicer2/+; nub-Gal4/UAS-CG8878-RNAi (I) adult wings. Defects in wing size (S), wing size and vein patterning (S-P), extra- or thicker veins (V+), defects in the wing margin (WM), and appearance of wing blisters (WA) are indicated in the upper-right corner of each picture.
Global parameters of kinases and phosphatases expression and knockdown phenotypes. Summary of the number of genes (TOTAL), genes analyzed (DONE), genes expressed in the wing disc (EXP), genes with a knockdown wing phenotype (PHE), gene knockdowns causing altered wing size (S), and gene knockdowns causing loss of wing or strong defects in wing size and pattern phenotype (S-P/nW).Global results of the RNAi screen for the complement of Drosophila kinases. (A) Fraction of kinases genes expressed from total (338 genes) and separated into the groups nonprotein kinases (Non-PK) and protein kinases (PK) of the classes AGC Kinases (AGC), Atypical protein kinases (APK), Calcium/Calmodulin-dependent protein kinases (CAMK), CK1 Kinases (CKI), CMGC Kinases (CMGC), other conventional protein kinase domains (OPK), Steryle20 kinases (STE), Tyrosine Kinases (TK), and Tyrosine kinase-like kinases (TLK). (B) Number of genes and percentages of genes with a knockdown mutant phenotype (dark gray sections of each column) or without mutant phenotype (light gray section of each column). Colored sectors show the percentage of each phenotype for nonprotein kinases (left) and for protein kinases (right). Lethality (L; dark blue sector), loss of wing (nW; green sector), changes in wing size and pattern (S-P; light blue sector), changes in size (S; yellow sector), loss of veins (V−; red sector), extra or thicker veins (V+; dark blue sector), wing differentiation defects (WD; orange sector), wing adhesion defects (WA; gray sector), and trichome differentiation or size defects (CD; purple sector). (C) Percentage of lethal and visible mutant phenotypes observed in the AGC, APK, CAMK, CKI, CMGC, OPK, STE, TK, and TKL classes using the same color code as above and indicated below the columns. (D–I) Representative examples of UAS-Dicer2/+; nub-Gal4/UAS-GFP (D), UAS-Dicer2/+; nub-Gal4/UAS-Ret-RNAi (E), UAS-Dicer2/+; nub-Gal4/UAS-gek-RNAi (F), UAS-Dicer2/+; nub-Gal4/UAS-Cdk12-RNAi (G), UAS-Dicer2/+; nub-Gal4/UAS-CKIa-RNAi (H) and UAS-Dicer2/+; nub-Gal4/UAS-CG8878-RNAi (I) adult wings. Defects in wing size (S), wing size and vein patterning (S-P), extra- or thicker veins (V+), defects in the wing margin (WM), and appearance of wing blisters (WA) are indicated in the upper-right corner of each picture.Carbohydrate, Lipid, and Nucleoside kinases include 101 proteins mostly involved in metabolic pathways (71%; Supplementary Table S1). The corresponding genes are generally expressed in the wing disc (84%; Figures 1 and 2A) and their knockdowns result in lethality or a wing phenotype in a low percentage of cases (29%; Figures 1 and 2B). The phenotypes most frequently observed after knockdown of nonprotein kinases consisted in a reduction of the size of the wing (S, 31%; Figures 1 and 2B) and defects in wing cuticle differentiation (WD, 13%; Figure 2B).Protein kinases comprise a single protein superfamily having a common catalytic structure (Morrison ). These enzymes are further subdivided into distinct groups based on their structural and functional properties (Hanks and Hunter 1995). Most of the 227 protein kinases genes are expressed in the wing disc (83%; Figures 1 and 2A) and in 53% of them we identified lethality or a mutant wing phenotype in UAS-dicer2/+; nub-Gal4/UAS-RNAi or UAS-dicer2/+; sal combinations (Figures 1 and 2, B and C and Table 1). The most frequent alterations observed were changes in the size of the wing (S), in many cases accompanied by changes in the position (size and pattern; S-P) or the differentiation (size and vein formation; S/V) of the veins (Table 1; Figure 2, B and C). Other changes in wing morphology consist in blisters, caused by a failure in the adhesion between the dorsal and ventral wing surfaces (wing adhesion; WA), or failures in the formation of the wing margin (WM; Figure 2, B and C). In general, protein kinases with a known function have a higher frequency of knockdown phenotypes than other kinases with less well-characterized functions (67% vs 40%, respectively). The phenotypes of gene knockdowns for kinases that have been previously characterized generally fits with the expectation. For example, knockdown of kinases regulating the phosphorylation and inactivation of Yorkie in the Hippo pathway result in wings larger than normal (Supplementary Figure S1B). Similarly, knockdown in components of the MAPK signaling pathway cause loss of veins and wing size-reduction phenotypes (Supplementary Figure S1C), whereas knockdown of genes belonging to the InR signaling pathway reduce the size of the wing without modifying the pattern of veins (Supplementary Figure S1E). Expected phenotypes were also observed for components of other signaling pathways such as Hedgehog (Supplementary Figure S1F), Notch (Supplementary Figure S1H), or Dpp (Supplementary Figure S1I), and for genes which activity is required for cell growth, division, adhesion, and survival (Supplementary Figure S1, D and J–I, respectively). These results suggest that the phenotypes of not previously characterized kinases in the wing disc would be informative as to their functional requirements.
Table 1
Drosophila kinases and phosphatases with a mutant wing phenotype after gene knockdown
Family
CG number
Name
H. Ortholog
Transformant
φ
f(x)
Ref.
GO
Kinases
CHK
CG13369
CG13369
RBKS
100,747
EPL
—
—
MET
CG3400
Pfrx
PFKFB3
25,959
S/V−
—
—
MET
IPK
CG45017
IP3K2
ITPKA-C
19,159
EPL/nec//S-P
Inositol hexakisphosphate substrate
Dean et al. (2015)
SIG
LK
CG10260
PI4KIIIα
PI4KA
105,614
S
SHW signaling
Yan et al. (2011)
CYT
CG2929
Pi4KIIalpha
PI4K2A
110,687
V−(acv)
1-phosphatidylinositol 4 substrate
Burgess et al. (2012)
PTR
CG31140
CG31140
DGKQ
101,347
WA(s)
—
—
MET
CG3682
PIP5K59B
PIP5K1A
108,104
L
1-phosphatidylinositol-4-phosphate 5 substrate
Khuong et al. (2010)
SIG
CG4141
Pi3K92E
PI3K92E
107,390
S(s)
Insulin signaling
Weinkove et al. (1999)
SIG
CG6355
fab1
PIKFYVE
27,591
S(s)/WM
Secretory/endocytic pathway
Rusten et al. (2006)
PTR
CG8657
Dgkepsilon
DGKE
4,659
S(s)
Diacylglycerol kinase activity
Frolov et al. (2001)
MET
CG9985
sktl
PIP5K 57B6
101,624
L//S-P(s)
A/B cell polarity
Claret et al. (2014)
CYT
NUBCK
CG11811
CG11811
GUK1
110,740
LPL/S/WD
Guanylate kinase activity
Gaudet et al. (2011)
MET
CG1725
dlg1
DLG1-4
109,274
S/WD
Polarity of larval imaginal cells
Bunker et al. (2015)
CA
CG3140
Ak2
AK2
107,326
EPL/nec
Adenylate kinase activity
Gaudet et al. (2011)
MET
CG32717
sdt
MPP5
100,685
WD
Zonula adherens assembly
Nam and Choi (2003)
CA
CG5757
CG5757
DTYMK
110,460
nW//wt
Nucleoside diphosphate kinase activity
Gaudet et al. (2011)
MET
CG5970
cbc
CLP1
100,686
LL/EPL
Polynucleotide 5'-hydroxyl-kinase activity
Gaudet et al. (2011)
RNA
CG6364
Uck
UCK2
108,949
nW
Nucleoside kinase activity
FlyBase Curators (2004)
MET
CG6612
Ak3
AK3
110,382
EPL/nec
Adenylate kinase activity
Gaudet et al. (2011)
MET
CG9541
CG9541
AK5
102,912
WA
Cytidylate kinase activity
Gaudet et al. (2011)
MET
OK
CG10702
CG10702
INSRR
100,842
S(w)
Receptor tyrosine kinase activity
Gaudet et al. (2011)
CA
CG12016
CG12016
NMRK1
103,613
S/WF(s)
Ribosylnicotinamide kinase activity
Gaudet et al. (2011)
MET
CG1939
Dpck
DCAKD
100,276
EPL
Dephospho-CoA kinase activity
Gaudet et al. (2011)
MET
CG3525
eas
ETNK1/2
103,784
S/WA/WM
Mushroom body development
Pascual et al. (2005)
MET
CG5025
Sps2
SEPHS1-2
105,268
WF(s)/ds/S
Selenide, water dikinase activity
Gaudet et al. (2011)
MET
CG8363
Papss
PAPSS1
110,544
EPL/nec/nW
Adenylylsulfate kinase activity
Gaudet et al. (2011)
MET
• Protein kinases
AGC
CG10033
for
FOR/PKG
108,293
S/WA
Feeding behavior
Allen et al. (2017)
PRO
CG10539
S6k
S6K
10539-R3
S(w)
Energy homeostasis
Allen et al. (2017)
SIG
CG12069
CG12069
PRK
23,719
WA(s)
—
—
PRO
CG12072
wts
WARTS
9,928
L//S(L)
SHW
Justice et al. (1995)
SIG
CG1210
Pdk1
PDK1
18,736
S(s)/F
Insulin
Cho et al. (2001)
SIG
CG17998
Gprk2
GPRK2
101,463
S-P(w)
Hh
Molnar et al. (2007)
SIG
CG2049
Pkn
PKN1/3
108,870
V+/S/CD
Rho effector
Betson and Settleman (2007)
CYT
CG4006
Akt1
AKT
103,703
S(s)
Insulin
Scanga et al. (2000)
SIG
CG4012
gek
GEK
4012R2
S(L)
Actin
Luo et al. (1997)
CYT
CG42783
aPKC
PRKCI/PRKCZ
105,624
nW//S-P(s)
A/B cell polarity
Kaplan et al. (2011)
CA
CG4379
Pka-C1
PKA Cl
101,524
S-P
Hh/MAPK
Ohlmeyer and Kalderon (1998)
SIG
CG6498
dop
MAST
35,100
WA(s)/V+
Tubulin
Hain et al. (2014)
CYT
CG8637
trc
NDR
107923
S/V+/WA
Actin
Geng et al. (2000)
CYT
CG9774
Rok
ROCK1
104,675
S/CD/WD
Actin
Mizuno et al. (1999)
CYT
A-PK
CG11859
RIOK2
RIOK2
109,296
LL/EPL/nec
Positive effect on glial cell proliferation
Read et al. (2013)
PRO
CG17603
Taf1
TAF1
106,119
LL/EPL
Regulation of RNA polymerase II
Gaudet et al. (2011)
DNA
CG3008
CG3008
103828
RIOK3
S-P
Maturation of SSU-rRNA
Gaudet et al. (2011)
RNA
CG32743
nonC
SMG1
41,990
S
NMD pathway
Long et al. (2010)
RNA
CG33554
Nipped-A
TRRAP
52,486
S-P(s)/CD
Histone acetylation
Gause et al. (2006)
DNA
CG3608
Adck
ADCK1
BL42841
WF/WD
—
—
MET
CG4252
mei-41
MEI41/FRP1
103,624
V+(w)
Cell cycle (DNA checkpoint)
Brodsky et al. (2000)
DNA
CG5092
Tor
MTOR
5092-R2
S(s)
Insulin/TOR pathway
Hennig et al. (2006)
SIG
CG5206
bon
TRIM24
101737
WM
chromatin organization
Beckstead et al. (2005)
PRO
CG8808
Pdk
PDK
106,641
S(w)
glucose homeostasis
Gaudet et al. (2011)
MET
CAMK
CG10177
CG10177
—
107,848
S/WA/V+
Secretory/endocytic pathway
Zacharogianni et al. (2011)
PTR
CG10895
lok
LOKI/CHK2
110,342
WA(s)/V+/S
DNA damage checkpoint
Xu et al. (2001)
DNA
CG14305
CG14305
TSSK1B
107,848
S(w)
—
—
PRO
CG1830
PhKgamma
PHKG1/2
110,638
WA(s)
—
—
PRO
CG3051
AMPKalpha
SNF1A
106,200
WF/S(s)/WA/+
Metabolism
Lee et al. (2007)
SIG
CG32666
Drak
DRAK1/2
107,263
nW//S-P(s)
Actin
Neubueser and Hipfner (2010)
CYT
CG33519
Unc-89
SPEG
106,267
V(+)/WA
Muscle
Schnorrer et al. (2010)
CYT
CG42347
sqa
MYLK1/2/3
101,640
V+(w)/WA
Actin
Tang et al. (2010)
CYT
CG42856
Sik3
SIK1/2/3
39,864
V+/WA
Insulin
Choi et al. (2015)
MET
CG4290
Sik2
SIK2
103,739
PL//wt
Energy homeostasis
Choi et al. (2011)
PRO
CG43143
Nuak1
NUAK1
45,401
S/WM
Autophagy
Brooks et al. (2020)
MET
CG4629
CG4629
NIM1K
26,574
WA
Glucose starvation
Gaudet et al. (2011)
MET
CG5408
trbl
TRIB2
106,774
WA(s)
Insulin signaling
Das et al. (2014)
MET
CG6703
CASK
CAKI
34,184
S/WA
NMJ
Sun et al. (2009)
PRO
CG6715
KP78a
MARK1-3
26,722
S/WA(s)/V+
—
—
CYT
CG7125
PKD
PRKD
106,255
L//S(s)/CD
Actin
Maier et al. (2006)
CYT
CG8485
CG8485
SNRK
35,940
S
—
—
PRO
CKI
CG2028
CkIα
CKIα
110,768
L/nW//S(s)/WA(s)
Hh/Wnt/SWH
Lum et al. (2003)
SIG
CG2577
CG2577
CSNK1A1
105,471
PL/S(s)/WA//S-P
—
—
PRO
CG6386
ball
VRK1
108,630
S-P(s)/CD
Histone phosphorylation
Aihara et al. (2004)
DNA
CG6963
gish
CKIγ
26,003
S/CD
Vesicle trafficking
Gaut et al. (2012)
PTR
CG8878
CG8878
–
100,985
S-P(s)
EGFR/MAPK
Ashton-Beaucage et al. (2014)
SIG
CMGC
CG10498
Cdk2
CDK2/CDC2c
104,959
L/nW//S-P(s)/WA
Cell cycle
Chen et al. (2003)
DIV
CG10572
Cdk8
CDK8
107,187
S/V+(w)
G1/S
Leclerc et al. (1996)
DIV
CG11489
srpk79D
SRPK1-3
47,544
WA
NMJ
Jonhson et al. (2009)
PRO
CG12559
rl
ERK1A
109,108
L//V−(s)/S(s)
Ras/MAPK
Brunner et al. (1994)
SIG
CG17090
Hipk
HIPK1
108,254
S(s)/WM
Positive regulation of Wnt signaling
Lee et al. (2009)
SIG
CG17520
CkIIα
CSNK2A1
BL31645
S-P(s)
Hh
Jia et al. (2010)
SIG
CG2621
sgg
GSK3β
101,538
L//WA/Q+/V+
Wnt
Peifer et al. (1994)
SIG
CG31003
gskt
GSK3β
25,641
S-P/WA
Male gamete generation
Kalamegham et al. (2007)
PRO
CG3319
Cdk7
CDK7
103,413
S
Cell cycle
Larochelle et al. (1998)
DIV
CG42273
mnb
MNB
28,628
S/V−
SHW/FoxO
Tejedor et al. (1995)
SIG
CG42320
Doa
CLK2
19,066
L//S-P
Autophagy
Tang et al. (2018)
MET
CG42366
CG42366
ICK/MAK
108,102
S(s)/WA(s)/V+
—
—
PRO
CG4268
Pitslre
CDK11B
107,303
EPL/nec//wt
Positive regulation of Toll signaling
Kanoh et al. (2015)
SIG
CG5072
Cdk4
CDK4/6
40,576
S/CD
JAK/STAT/TOR
Kim et al. (2017)
DIV
CG5179
Cdk9
CDK9
103,561
L//S-P(s)/CD/WA
Histone methylation
Eissenberg et al. (2007)
DIV
CG5363
Cdk1
CDK1/CDC2
106,130
L//S-P(s)/CD/WA
Cell cycle
Stern et al. (1993)
DIV
CG7028
CG7028
PRP4
107,042
PL/nW//S-P(s)
Splicing
Herold et al. (2009)
RNA
CG7393
p38b
MAPK14
108,099
WA(s) (29°)
MAPK cascade
Han et al. (1998)
IMM
CG7597
Cdk12
CDK12/13
BL34838
S-P(s)
Transcription
Bartkowiak et al. (2010)
DNA
CG7892
nmo
NEMO/NLK
104,885
V+(s)/WA(s)/S
Wg/Dpp
Zeng and Verheyen (2004)
SIG
O-PK
CG1098
Madm
NRBP1
101,758
S(s)
Cell growth and proliferation
Gluderer et al. (2010)
PTR
CG1107
aux
GAK
16,182
L//S-P/WA
Clathrin
Hagedorn et al. (2006)
PTR
CG11221
meng
SBK1
42,947
S/WF
Memory
Lee et al. (2018)
PRO
CG1227
CG1227
MPSK/PSK
105,610
L//S-P
—
—
PRO
CG12306
polo
POLO/PLK1
20,177
L/nW//S-P(s)/CD
Cell cycle
Carmena et al. (1998)
DIV
CG14030
Bub1
BUB1
101,096
S/WA/WM
Cell cycle
Logarinho et al. (2004)
DIV
CG2087
PEK
EIF2AK3
16,427
V+/WA(s)
—
—
PRO
CG3068
aur
AURORA
108,446
S-P(s)
Cell cycle
Glover et al. (1995)
DIV
CG32417
Myt1
MYT1
105,157
WA
Cell cycle
Price et al. (2002)
DIV
CG32742
Cdc7
CDC7
40,715
S
Cell cycle
Stephenson et al. (2015)
DNA
CG34412
tlk
TLK1
46,426
L//S(s)/V+
Cell cycle
Carrera et al. (2003)
DIV
CG5790
CG5790
CDC7
45,044
S/V+
Cell cycle
Stephenson et al. (2015)
DNA
CG6551
fu
FUSED
6551R3
S-P
Hh/Dpp
Robbins et al. (1997)
SIG
CG6620
aurB
AURKA/B/C
104,051
S-P(s)/CD
Cell cycle
Giet et al. (2001)
DIV
CG7177
Wnk
WNK1
106,928
S(s)
Wing disc development
Serysheva et al. (2013)
PRO
CG7838
BubR1
BUB1
26,109
S/V+/CD
Cell cycle
Logarinho et al. (2004)
DIV
CG9746
Vps15
PIK3R4
BL34092
V+
Autophagy
Lindmo et al. (2008)
SIG
STE
CG10295
Pak
PAK2
12,553
WA
AJ
Harden et al. (1996)
CYT
CG11228
hpo
MST2
104,169
L//S(L)/WF
SHW
Udan et al. (2003)
SIG
CG14217
Tao
TAO1
17,432
WF/V+//S(L, w)/V+
SHW
Poon et al. (2011)
SIG
CG14895
Pak3
PAK3
107,260
S(L)
Cytoskeleton actin//MAPK
Mentzel and Raabe (2005)
CYT
CG15793
Dsor1
SOR
40,026
nW//S(s)/V−
EGFR/MAPK
Tsuda et al. (1993)
SIG
CG16973
msn
NIK
101,517
S/WA/V+(w)/CD
JNK
Su et al. (1998)
SIG
CG18582
mbt
STE20
10,9880
S(w)/WA
AJ
Menzel et al. (2008)
CA
CG4527
slik
SLK
43,784
S
Cell cycle
Hipfner and Cohen (2003)
DIV
CG5169
GckIII
STLK3
49,558
S/V+(w)/CD
SJ
Song et al. (2013)
PRO
CG7693
fray
STK39
106,919
S/WA
Ion homeostasis
Li et al. (2019)
PRO
CG7717
Mekk1
MAP3K4
110,339
S
JNK
Inoue et al. (2001)
SIG
CG9738
Mkk4
SEK1/MKK4
9738-R1
S
JNK
Han et al. (1998)
SIG
TKL
CG10776
wit
TGFBR2
42,244
WA(s)
BMP
Zheng et al. (2003)
SIG
CG14026
tkv
BMPR1
862
S-P(s)
Dpp
Penton et al. (1994)
SIG
CG1891
sax
ACVR1
1891-R3
V±/S
Dpp
Nellen et al. (1994)
SIG
CG2272
slpr
MAP3K9/10
106,449
S/V+/WA
JNK
Stronach and Perrimon (2002)
SIG
CG2845
phl
RAF
CG4803
S(s)/V−
EGFR/MAPK
Douziech et al. (2006)
SIG
CG2899
ksr
KSR
110,621
S(s)/V−
EGFR/MAPK
Douziech et al. (2006)
SIG
CG31421
Takl1
MAP3K7
BL55903
S
JNK
Wong et al. (2013)
SIG
CG4803
Takl2
MAP3K7
104,701
V+/WA/S/N
—
—
PRO
CG7904
put
TGFBR2
7904-R2
S-P(s)
Dpp
Ruberte et al. (1995)
SIG
CG8224
babo
TGFBR1
106,092
WF(s)//S
TGFβ
Brummel et al. (1999)
SIG
CG10079
Egfr
EGFR
10079-R2
nW//S(s)/V−
EGFR/MAPK
Livneh et al. (1985)
SIG
CG14396
Ret
RET
843
WA(s)
Actin
Soba et al. (2015)
CA
CG14992
Ack
TNK2
39,857
PL//S/V+(w)/WA
Negative regulation of hippo signaling
Schoenherr et al. (2012)
SIG
CG18085
sev
SEV
107,048
S
MAPK
Baslet et al. (1991)
SIG
CG18402
InR
INS RECEPTOR
992
S
Insulin
Yamaguchi et al. (1995)
SIG
CG42317
Csk
CSK
32,877
WA(w)//S(L)
SRC/JNK/JAK-STAT
Read et al. (2004)
SIG
CG44128
Src42A
SRC 42A
26,019
S(s)/V−
AJ
Shindo et al. (2008)
SIG
CG7524
Src64B
SRC 64B
35,252
S(w)
Actin
Djagaeva et al. (2005)
SIG
CG7525
Tie
—
7525-R2
S/V+/WF
Cell survival
Bilak et al. (2014)
SIG
CG8222
Pvr
FLT1
105,353
PL/nW//S-P
EGFR/MAPK and TORC1
Tran et al. (2013)
SIG
Phosphatases
5’N
CG4827
veil
NT5E
100,050
S(w)
5'-nucleotidase activity
Fenckova et al. (2011)
MET
AP
CG3292
Alp7
ALPPL2
19,989
PL/nec
—
—
MET
CG5567
CG5567
PGP
106,981
WA
—
—
PRO
CG8105
Alp11
ALPI
104,510
WA
—
—
CGh
LP
CG11437
CG11437
PPAP1-2
9,452
WA
—
—
MET
CG11440
laza
PPAP2
42,592
S/V+/WA
Phototransduction
Garcia-Murillas et al. (2006)
MET
CG8709
Lpin
LPIN3
107,707
WS(dp)/F
Lipid homeostasis
DNA
SP
CG3400
Pfrx
PFKFB
25,959
S/V−
—
—
MET
IPP
CG15743
CG15743
IMPAD1
42,686
S
—
—
SIG
CG17029
CG17029
IMPA1/2
49,565
WA
Autophagy
Allen et al. (2020)
MET
CG4123
Mipp1
MINPP1
101,634
S/V−(cv)/WD
Regulation of filopodium assembly
Cheng and Andrew, (2015)
MET
CG42271
CG42271
INPP4A
100,176
WA (s)/V+
—
—
MET
CG42283
5PtaseI
INPP5A
33,768
WA/V+/S
Autophagy
Allen et al. (2020)
MET
CG5671
Pten
PTEN
35,731
S(L)
Insulin
Goberdhan et al. (1999)
SIG
CG6562
Synj
SYNJ1/2
46,070
V+(w)
Synapsis
Dickman et al. (2005)
PTR
CG9128
Sac1
SACM1L
44,376
LPL/nec
Cytoplasmic microtubule organization
Forrest et al. (2013)
SIG
CG9389
CG9389
IMPA1/2
44,663
S(w)
Signaling
Gaudet et al. (2011)
SIG
CG9784
CG9784
INPP5K/J
108,075
WA
Signaling
Gaudet et al. (2011)
SIG
HAD-NPP
CG1814
CG1814
NT5DC3
106,195
WA/WD
—
—
DNA
CG3705
aay
PSPH
110,661
WD
—
—
MET
CG5177
CG5177
103,024
LL/EPL/nec
NOT trehalose-phosphatase activity
Yoshida et al. (2016)
MET
CG5567
CG5567
PGP
106,981
WA
—
—
PRO
• Protein phosphatases
HAD-PP
CG12078
CG12078
CTDNEP1
101,274
WA
—
—
PRO
CG12252
Fcp1
CTDP1
106,253
PL/nec
Polytene chromosome
Tombácz et al. (2009)
DNA
CG1696
Dd
CTDNEP1
104,785
S(L)/V−(L4)
Imaginal disc wing vein specification
Liu et al. (2011)
PRO
CG2713
ttm50
TIMM50
103,638
EPL/nec
Mitochondrion organization
Sugiyama et al. (2007)
TRA
C-PTP
CG14297
CG14297
ACP1
102,071
S/V−(w)/WA
—
—
PRO
CG32697
Ptpmeg2
PTPN9
104,427
EPL/nec
Border follicle cell migration
Chen et al. (2012)
PRO
CG33747
primo-2
ACP1
23,081
L/nW//S-P
—
—
PRO
CG3954
csw
PTPN6, 11
108,352
V−/S/WA
EGFR/MAPK
Perkins et al. (1996)
SIG
CG9181
Ptp61F
PTPN1-2
108,888
S(w)
EGFR/MAPK
Tchankouo et al. (2014)
PRO
CG9311
mop
PTPN23
104,860
S/V+
MAPK/SHW
Gilbert et al. (2011)
SIG
DSP
CG10089
CG10089
DUSP15/22
17,991
S/V+
—
—
PRO
CG13197
CG13197
DUSP11
105,122
S
—
—
PRO
CG1395
stg
CDC25
17,760
L//S-P(s)
Cell cycle
Edgar and O’Farrell (1990)
DIV
CG14080
Mkp3
DUSP7
23,911
V+(w)
EGFR/MAPK
Ruiz-Gómez et al. (2005)
SIG
CG14211
MKP-4
DUSP12
104,884
L/nW//S-P
JNK
Sun et al. (2008)
SIG
CG14411
CG14411
MTMR10
109,622
S(w)
NOT PTP activity
Hatzihristidis et al. (2015)
PRO
CG1810
mRNA-cap
RNGTT
3,798
L//S-P(s)
Hh
Chen et al. (2017)
RNA
CG3530
Mtmr6
MTMR6-8
26,217
S(w)
Cell cycle
Chen et al. (2007)
DIV
CG3632
CG3632
MTMR4
110,167
WM(s)
Regulation of autophagy
Gaudet et al. (2011)
PRO
CG4965
twe
CDC25A-C
46,064
V−
Meiosis
Alphey et al. (1992)
DIV
CG7850
puc
DUSP10
3,018
L//S-P
JNK
Martín-Blanco et al. (1998)
SIG
PPM
CG17746
CG17746
PPM1A
100,178
WF(s)/S
—
—
PRO
CG2984
Pp2C1
PPM1D
33,599
V/WM
—
—
PRO
PPP
CG10930
PpY-55A
PPP1CB
102,021
nW//wt
—
—
PRO
CG12217
PpV
PPP6C
101,997
L//S-P
JNK
Chi et al. (2018)
PRO
CG17291
Pp2A-29B
PPP2R1A
49,672
L//S-P(s)
Cell cycle
Goshima et al. (2007)
PRO
CG2096
flw
PPP1CB
104,677
S/WM
Myosin
Kirchner et al. (2007)
PRO
CG2890
PPP4R2r
PPP4R2
105,399
L//S/V+
Cell cycle
Chen et al. (2007)
PRO
CG32505
Pp4-19C
PP4C
25,317
nW//S-P(s)
Cell cycle
Helps et al. (1998)
PRO
CG5643
wdb
PP2A/wdb
101,406
S
Cell cycle
Chen et al. (2007)
PRO
CG5650
Pp1-87B
PPP1CA-C
35,025
L//S-P
Cell cycle
Cohen (1997)
PRO
CG6235
tws
PPP2R2A-D
34,340
S/V−/WA
Cell cycle
Brownlee et al. (2011)
PRO
CG6593
Pp1α-96A
PPP1C A-C
27,673
nW//S-P(s)
Wg/Hh
Swarup et al. (2015)
PRO
CG7109
mts
PPP2CA-B
35,171
nW//S-P
Wg/Hh/MAPK
Zhang et al. (2009)
PRO
CG8402
PpD3
PPP5C
24,309
V+/WA
Cell cycle
Chen et al. (2007)
PRO
UN-PPP
CG14216
Ssu72
SSU72
104,388
WM(w)S(w)
Regulation RNA polymerase II
Werner-Allen et al. (2011)
RNA
R-PTP
CG10975
Ptp69D
PTPRC
27,090
S/CD
Axon guidance
Desai et al. (1997)
PRO
CG6899
Ptp4E
PTPRB
1,012
S
Axon guidance
Jeon et al. (2008)
PRO
Protein family (Family), CG number, gene name (Name), human ortholog (H. Ortholog), transformant RNAi line (Transformant), wing knockdown phenotype (Φ) and main described function [f(x)], representative reference (Ref.), and molecular classification (GO) into the classes general sugar and lipid metabolism (MET), signaling (SIG), cytoskeleton organization (CYT), protein transport across membranes (PTR), cell adhesion (CA), RNA biology (RNA), DNA biology (DNA), protein modifications (PRO), cell division (DIV), immunological responses (IMM), and solute transport (TRA). The abbreviations used to describe each phenotype are described in the main text. The list of references is presented as Supplementary material.
Drosophila kinases and phosphatases with a mutant wing phenotype after gene knockdownProtein family (Family), CG number, gene name (Name), human ortholog (H. Ortholog), transformant RNAi line (Transformant), wing knockdown phenotype (Φ) and main described function [f(x)], representative reference (Ref.), and molecular classification (GO) into the classes general sugar and lipid metabolism (MET), signaling (SIG), cytoskeleton organization (CYT), protein transport across membranes (PTR), cell adhesion (CA), RNA biology (RNA), DNA biology (DNA), protein modifications (PRO), cell division (DIV), immunological responses (IMM), and solute transport (TRA). The abbreviations used to describe each phenotype are described in the main text. The list of references is presented as Supplementary material.We were able to identify a phenotype for 40% of protein kinases not previously characterized in the Drosophila wing. These phenotypes could now be used as an entry point to perform a more detailed functional characterization of the corresponding genes and proteins. Despite the high fraction of genes that knockdown results in wings with altered morphogenesis, there are still many cases of genes expressed in the wing disc and for which we could not detect a mutant phenotype upon expression of the corresponding RNAi (208 genes). The reason for this result could be either a genuine lack of requirement of the gene during wing development, gene redundancy in those cases where multiple kinases affect a similar set of targets, or insufficient reduction in the level of mRNA following the RNAi knockdown. Focusing on those cases in which the expression of RNAi results in wings with altered size and/or vein patterns, we did not find a particular phenotypic enrichment for a given family of protein kinases (Figure 2C). Many of the phenotypes we found are reminiscent of those caused by alterations of specific signaling pathways in the wing. For example, knockdown of genghis khan (gek), the fly orthologous to human CDC42 binding protein kinase alpha, results in wings larger than normal (Figure 2F), similar to increased Yorki activity. The Gek protein is a putative effector for Drosophila Cdc42, which promotes Actin polymerization during Drosophila oogenesis (Luo ), and the Actin cytoskeleton is a key mediator of the regulation of Hippo signaling (Seo and Kim 2018). In contrast, loss of Ret reduces wing size and causes a wing blisters (Figure 2E), which is compatible with the requirement of the gene in extracellular matrix adhesion during dendrite development (Soba ). Loss of cdk12, encoding a transcription elongation-associated CTD kinase (Bartkowiak ), results in ectopic vein formation and loss of wing margin structures reminiscent of loss of Notch signaling (Figure 2G). Strong effects in wing size and pattern were observed upon knockdown of several kinases such as Cdk9 (Supplementary Figure S2), which is involved in RNA polymerase II elongation control (Peng ), CKIalpha (Fig. 2H), which is involved in multiple signaling pathways (see, e.g., Apionishev ) and nonC (Supplementary Figure S3), related to the nonsense-mediated mRNA decay pathway (Rehwinkel ). Other protein kinases affecting the veins may do so by altering the early secretory pathway (CG10177 in Supplementary Figure S4, see Zacharogianni ), the endocytic pathway (Vps15; Supplementary Figure S3; see O’Farrell ), or gene expression, such as Cdk8 (Supplementary Figure S2; see Loncle ) and CG8878 (Fig. 2I; see McCracken and Locke 2014). Knockdown of other kinases with totally unknown function such as Nuak1 (S/WM: Supplementary Figure S4), CG1227 (S-P; Supplementary Figure S3), RIOK1 (S/WA; Supplementary Figure S3), and CG2577 (S-P; Supplementary Figure S3) also affect wing development in specific ways. The full collection of wings showing a phenotype distinct to wild type is shown in Supplementary Figures S1–S5.
Phenotypic screen of phosphatases in the wing
Phosphatases catalyze the hydrolysis of a phosphate group from a given substrate. We included in our analysis 79 nonprotein phosphatases, 99 protein phosphatases, and 14 unclassified phosphatases (Figures 1 and 3A). These genes are expressed in the wing disc with percentages varying from 64% for unclassified phosphatases to 73% for protein phosphatases (Figure 3A). Nonprotein phosphatases include proteins with broad substrate specificity (acid and alkaline phosphatases), lipid phosphate phosphatases (LPP), which are integral membrane proteins that catalyze the dephosphorylation of a variety of lipid phosphates, phosphatidylinositol lipid phosphatases, sugar phosphatases, and HAD family nonprotein phosphatases. The genes CG9115, CG3632, CG3530, and CG5026, which have Phosphoinositide 3 phosphatase activity, also have Dual-Specificity Phosphatases (DSP) activity, and they were classified in this last group. A large fraction of these genes (88%) is related to metabolism (Supplementary Table S1). The frequency of lethality or wing mutant phenotype for this group of genes is low (31%; Figures 1 and 3B), and is only above average for phosphatidylinositol lipid phosphatase enzymes (45%; Table 1). These proteins remove phosphate groups from positions 3, 4, or 5 of inositol molecules, participating in the metabolism of phosphoinositides. Although these lipids bind a variety of target proteins mediating cell membrane functions including vesicular trafficking, signaling, and cytoskeletal function (Balakrishnan ) phosphatidylinositol lipid phosphatases were classified mostly in the metabolism class.
Figure 3
Global results of the RNAi screen for the complement of Drosophila phosphatases. (A) Fraction of phosphatase genes expressed in the wing disc separated into the groups nonprotein phosphatases (Non-PP; 79 genes), unclassified phosphatases (Un-P; 14 genes), and protein phosphatases (PP; 99 genes). Protein phosphatases were further subdivided into the groups serine-threonine protein phosphatases of the classes HAD, PPP, PPM, and unclassified (HAD-PP, PPP, PPM, and Un-PPP, respectively), Tyrosine phosphatases, including cytosolic (C-PTP) and receptor proteins (R-PTP), Histidine phosphatases (PHP), and DSP. (B) Number of nonprotein phosphatases (left) and protein phosphatases (right) for which we tested its knockdown phenotype, and fraction of genes with a mutant phenotype (dark gray section) or without any phenotype (light gray section) in knockdown conditions. Colored sectors show the percentage of each phenotype for nonprotein phosphatases (left) and for protein phosphatases (right). Lethality (L; dark blue sector), loss of wing (nW; green sector), changes in wing size and pattern (S-P; light blue sector), changes in size (S; yellow sector), loss of veins (V−; red sector), extra or thicker veins (V+; dark blue sector), wing adhesion defects (WA; gray sector), trichome differentiation or size defects (CD; purple sector), and other phenotypes (WS; dark gray sector). (C) Percentage of lethal (blue) and visible mutant phenotypes respect the total number of observed phenotypes in the HAD-PP, C-PTP, DSP, PPM, PPP, UN-PPP, and R-PTP classes. (D) Control nub-Gal4/UAS-GFP wing. (E–I) Representative mutant wings (E) UAS-Dicer2; nub-Gal4/UAS-csw-RNAi wing (csw-i) showing the expected loss of veins phenotype. (F) UAS-Dicer2/+; sal (mRNAcap-i). (G) UAS-Dicer2/+; nub-Gal4/UAS-laza-RNAi (laza-i). (H) UAS-Dicer2/+; sal (Pp2A-28B-i). (I) UAS-Dicer2/+; nub-Gal4/UAS-Pp2C1-RNAi (Pp2C1-i).
Global results of the RNAi screen for the complement of Drosophila phosphatases. (A) Fraction of phosphatase genes expressed in the wing disc separated into the groups nonprotein phosphatases (Non-PP; 79 genes), unclassified phosphatases (Un-P; 14 genes), and protein phosphatases (PP; 99 genes). Protein phosphatases were further subdivided into the groups serine-threonine protein phosphatases of the classes HAD, PPP, PPM, and unclassified (HAD-PP, PPP, PPM, and Un-PPP, respectively), Tyrosine phosphatases, including cytosolic (C-PTP) and receptor proteins (R-PTP), Histidine phosphatases (PHP), and DSP. (B) Number of nonprotein phosphatases (left) and protein phosphatases (right) for which we tested its knockdown phenotype, and fraction of genes with a mutant phenotype (dark gray section) or without any phenotype (light gray section) in knockdown conditions. Colored sectors show the percentage of each phenotype for nonprotein phosphatases (left) and for protein phosphatases (right). Lethality (L; dark blue sector), loss of wing (nW; green sector), changes in wing size and pattern (S-P; light blue sector), changes in size (S; yellow sector), loss of veins (V−; red sector), extra or thicker veins (V+; dark blue sector), wing adhesion defects (WA; gray sector), trichome differentiation or size defects (CD; purple sector), and other phenotypes (WS; dark gray sector). (C) Percentage of lethal (blue) and visible mutant phenotypes respect the total number of observed phenotypes in the HAD-PP, C-PTP, DSP, PPM, PPP, UN-PPP, and R-PTP classes. (D) Control nub-Gal4/UAS-GFP wing. (E–I) Representative mutant wings (E) UAS-Dicer2; nub-Gal4/UAS-csw-RNAi wing (csw-i) showing the expected loss of veins phenotype. (F) UAS-Dicer2/+; sal (mRNAcap-i). (G) UAS-Dicer2/+; nub-Gal4/UAS-laza-RNAi (laza-i). (H) UAS-Dicer2/+; sal (Pp2A-28B-i). (I) UAS-Dicer2/+; nub-Gal4/UAS-Pp2C1-RNAi (Pp2C1-i).Protein phosphatases (99 members) belong to four groups: Haloacid Dehalogenases (HAD-PP; Burroughs ), Histidine phosphatases and the more numerous Serine/Threonine Phosphatases and Tyrosine phosphatases (Morrison ; Hatzihristidis ). These genes are generally expressed in the wing disc (73%, Figure 3A), ranging from 60% in the case of Serine/Threonine Phosphatases of the PPP group to 96% for DSP (Figures 1 and 3A). Some DSP can also dephosphorylate nonprotein targets including phosphoinositide, RNA 5'-triphosphate, and carbohydrates (Hatzihristidis ).The frequency of nub-Gal4/UAS-RNAi combinations with a lethal or altered wing phenotype for protein phosphatase genes was 40% (Figure 3B), reaching higher values for cytoplasmic tyrosine phosphatases (60%; Figure 1) and DSP (52%; Figure 1). For proteins with a known function the phenotype was as expected. For example, csw, acting downstream of receptor tyrosine kinases (Johnson Hamlet and Perkins 2001), displayed a loss of vein phenotype (Figure 3E), and mRNA-CAP, which regulates Hh signaling through antagonizing PKA (Chen ) has strong size and pattern effects (Figure 3F). Inositol and Lipid phosphatases, such as 5PtaseI and laza (Figure 3G), display a similar extra-vein phenotype, suggestive of increased EGFR signaling. Both of them also have adhesion defects between dorsal and ventral surfaces of the wing (WA phenotype). This is a common feature of the knockdown of other phosphoinositide phosphate phosphatases such as CG9784, CG11477, and CG17029 (Supplementary Figure S6). Particularly strong phenotypes were observed in the case of genes encoding different subunits of the protein phosphatase type 2A complex (PP2A), which modulates the insulin (Kulkarni ), Hedgehog (Su ), and Wingless (Luo ) signaling pathways. For example, knockdown of Pp2A-29B, encoding the structural A subunit of PP2A phosphatase enzyme (Chen ) prevents wing development (Figure 3H). A similar phenotype is observed in Pp1α-96A knockdown flies (Supplementary Figure S6). This protein also has multiple functions including the regulation of the Hedgehog and Wingless signaling pathways (Su ). The knockdown of several PPP Serine/Threonine phosphatases results in lethality (nub-Gal4) and defects in wing size and pattern (sal) with a phenotype similar to Pp2A-29B knockdown (Figure 3H). Some examples are mts, Pp1-87B, Pp1alpha-96A, Pp4-19C, PPP4R2r, a component of the protein phosphatase 4 complex that may coordinate centrosome maturation and cell migration (Chen ), Pp2A-29B and PpV, encoding the catalytic subunit of PP6 [Supplementary Figure S6, PPP family and see Ma ]. A similar strong phenotype, in which all the central domain is differentiated as vein tissue, is also observed for Pp2C1 (Figure 3I). In contrast, knockdown of the protein tyrosine phosphatases Ptp69D and Ptp4E, which might mediate negative regulation of the receptors EGFR, Breathless, and Pvr (Jeon ), results only in defects in wing size (Supplementary Figure S7). The DUSP family offers a wide range of wing phenotypes including extra veins (CG10089), lack of veins (twe), size defects (CG13197, Mtmr6), and severe size and pattern defects (stg, mRNAcap, Mkp4 and Puc). The complete collection of phenotypes for protein and inositide phosphatases is shown in Supplementary Figure S6 and S7.
Developmental bases for “wing size” and “wing size and pattern” defects
The most common phenotypes observed in UAS-RNAi/nub-Gal4 and UAS-RNAi/sal combinations are those in which the size of the wing is altered, most frequently reduced (see, e.g., Figures 2E and 3, E, G, and I). This phenotype could be caused by a reduction in the number of wing cells (due to cell death or reduced cell division in the imaginal disc), by a reduction in the size of the cells, or by a combination of these two effects. We analyzed cell division (mitotic index) and death in the wing imaginal disc and cell size in the adult wing for four genetic combinations with different degrees of wing size reduction (Figure 4). In wild-type imaginal discs, cell division (mitosis) occurs throughout the presumptive wing blade and cell death is only testimonial and scattered in the disc (Figure 4, A and B). In the combinations analyzed the mitotic index in the wing pouch region was reduced, from 47% (nub-Gal4/UAS-fab1-RNAi; Figure 4C) to 24% (nub-Gal4/UAS-CG14297-RNAi; Figure 4E). Cell size in the adult wing was also generally reduced, from 29% (nub-Gal4/UAS-Cdc7-RNAi; Figure 4D) to 14% (nub-Gal4/UAS-fab1-RNAi; Figure 4C). The occurrence of cell death in wing discs corresponding to smaller adult wings was generally low (Figure 4, C–F). These observations suggest that reduced wing size is mostly due to a lower rate of mitosis accompanied by different degrees of cell size reduction.
Figure 4
Cell proliferation and viability of genetic combinations affecting wing size. (A-B) Wing phenotype (A and B), expression of phospho-Histone3 (pH3; red in A’ and B’) and cleaved-Dcp1 (DcpI*, white in A’’ and B’’) in control UAS-Dicer2; nub-Gal4/UAS-GFP third instar wing discs grown at 25°C (A–A’’) and 29°C (B–B’’). (C–F) Wing phenotype (C–F), expression of phospho-Histone3 (pH3; red in C’–F’), and cleaved-Dcp1 (DcpI*, white in C’’–F’’) in the genetic combinations UAS-Dicer2; nub-Gal4/UAS-fab1-RNAi (C–C’’), UAS-Dicer2; nub-Gal4/UAS-cdc7-RNAi (D–D’’), UAS-Dicer2; nub-Gal4/UAS-CG14297-RNAi (E–E’’), and UAS-Dicer2; nub-Gal4/UAS-Takl2-RNAi (F–F’’). Below each wing is indicated the percentage of wing size (Size), cell size (cell size), and wing cell number (cell no.) modification for each genetic combination compared to their control UAS-Dicer2; nub-Gal4/UAS-GFP wings.
Cell proliferation and viability of genetic combinations affecting wing size. (A-B) Wing phenotype (A and B), expression of phospho-Histone3 (pH3; red in A’ and B’) and cleaved-Dcp1 (DcpI*, white in A’’ and B’’) in control UAS-Dicer2; nub-Gal4/UAS-GFP third instar wing discs grown at 25°C (A–A’’) and 29°C (B–B’’). (C–F) Wing phenotype (C–F), expression of phospho-Histone3 (pH3; red in C’–F’), and cleaved-Dcp1 (DcpI*, white in C’’–F’’) in the genetic combinations UAS-Dicer2; nub-Gal4/UAS-fab1-RNAi (C–C’’), UAS-Dicer2; nub-Gal4/UAS-cdc7-RNAi (D–D’’), UAS-Dicer2; nub-Gal4/UAS-CG14297-RNAi (E–E’’), and UAS-Dicer2; nub-Gal4/UAS-Takl2-RNAi (F–F’’). Below each wing is indicated the percentage of wing size (Size), cell size (cell size), and wing cell number (cell no.) modification for each genetic combination compared to their control UAS-Dicer2; nub-Gal4/UAS-GFP wings.The second most frequent class of mutant phenotypes includes strong changes in the size of the wing accompanied by alterations in the pattern of veins. For many of these cases, the expression of RNAi in the entire wing (nub-Gal4) resulted in PL, and the effects in the wing could only be analyzed in combinations with the weaker driver sal (Table 1). We analyzed cell death and mitosis in three sal combinations leading to the formation of small wings with aberrant venation patterns and found that some but not all of them are accompanied by massive cell death in the wing disc (Figure 5). This result indicates that the corresponding genes are required for cell viability and suggest that many genetic combinations in which the size and pattern of the wing are severely affected are a consequence of continuous and massive cell death in the imaginal disc epithelium.
Figure 5
Cell proliferation and viability of genetic combinations affecting wing size and pattern. (A) UAS-Dicer2; sal control wing. (A’–A’’’) Late third instar wing disc of UAS-Dicer2; sal genotype showing the expression of GFP (GFP; green in A’–A’’), phospho-Histone 3 (pH3; red in A’), cleaved-Dcp1 (white in A’’’), and Topro3 (topro; blue in A’’). (B) Adult female wings of UAS-Dicer2; sal. (B’–B’’’) Late third instar wing disc of UAS-Dicer2; sal genotype showing the expression of GFP (green in B’–B’’), phospho-Histone 3 (pH3; red in B’), cleaved-Dcp1 (DcpI*; white in B’’’), and Topro3 (topro; blue in B’’). (C) UAS-Dicer2; sal. (C’–C’’’) Late third instar wing disc of UAS-Dicer2; sal genotype showing the expression of GFP (GFP; green in C’–C’’), phospho-Histone 3 (pH3; red in C’), cleaved-Dcp1 (DcpI*; white in C’’’), and Topro3 (topro; blue in C’’). (D) UAS-Dicer2; sal. (D’–D’’’) Late third instar wing disc of UAS-Dicer2; sal genotype showing the expression of GFP (green in D’–D’’), phospho-Histone 3 (pH3; red in D’), cleaved-Dcp1 (DcpI*; white in D’’’), and Topro3 (blue in H’). Below the wing discs shown in B’, C’, D’ percentage of mitotic index reduction for each genetic combination compared to their control UAS-Dicer2; sal discs.
Cell proliferation and viability of genetic combinations affecting wing size and pattern. (A) UAS-Dicer2; sal control wing. (A’–A’’’) Late third instar wing disc of UAS-Dicer2; sal genotype showing the expression of GFP (GFP; green in A’–A’’), phospho-Histone 3 (pH3; red in A’), cleaved-Dcp1 (white in A’’’), and Topro3 (topro; blue in A’’). (B) Adult female wings of UAS-Dicer2; sal. (B’–B’’’) Late third instar wing disc of UAS-Dicer2; sal genotype showing the expression of GFP (green in B’–B’’), phospho-Histone 3 (pH3; red in B’), cleaved-Dcp1 (DcpI*; white in B’’’), and Topro3 (topro; blue in B’’). (C) UAS-Dicer2; sal. (C’–C’’’) Late third instar wing disc of UAS-Dicer2; sal genotype showing the expression of GFP (GFP; green in C’–C’’), phospho-Histone 3 (pH3; red in C’), cleaved-Dcp1 (DcpI*; white in C’’’), and Topro3 (topro; blue in C’’). (D) UAS-Dicer2; sal. (D’–D’’’) Late third instar wing disc of UAS-Dicer2; sal genotype showing the expression of GFP (green in D’–D’’), phospho-Histone 3 (pH3; red in D’), cleaved-Dcp1 (DcpI*; white in D’’’), and Topro3 (blue in H’). Below the wing discs shown in B’, C’, D’ percentage of mitotic index reduction for each genetic combination compared to their control UAS-Dicer2; sal discs.
Quantitative changes in the activity of the EGFR signaling pathway are translated into phenotypic series affecting wing vein formation and wing size
The EGFR signaling pathway contributes to the regulation of imaginal cell division, growth, viability, and differentiation (Shilo 2003). The pathway includes a Tyrosine kinase transmembrane protein as receptor (EGFR) and several protein kinases and phosphatases that participate as core components of the receptor intracellular signal transduction cascade (Shilo 2003). In order to search for additional protein kinases and phosphatases that could impinge on the EGFR signaling cascade, we used genotypes in which the activity of the pathway is modified at the level of the receptor or at the level of the MAP kinase ERK (rolled). For both EGFR and ERK, we aimed to modify the phenotype resulting from higher than normal activation (EGFR, respectively) or by lower than normal activation (EGFR-RNAi and rolled-RNAi, respectively) by the coexpression of RNAi’s targeting all protein kinases and phosphatases. As a preliminary experiment, we generated genotypes with different degrees of EGFR and ERK variants overexpression. To do this, we changed the number of doses of the Gal4 insertions used and also the temperature at which the flies were raised. We were able to establish for each case a clear phenotypic series of effects, suggesting a linear translation between EGFR signaling output and wing phenotype (Figure 6). For example, in the cases of EGFR pathway insufficiency caused by the expression of RNAi directed against EGFR or ERK the wing becomes progressively smaller as the level of RNAi expression increases (Figure 6A, EGFR-i and rolled-i columns). Simultaneously, the number of veins is also progressively reduced, from small gaps in the L4 vein (low expression of RNAi, upper panels in Figure 6) to the absence of all the veins included in the domain of sal expression (L2, L3, and L4; high expression of RNAi; lower panels in Figure 6A). Conversely, expression of activated forms of EGFR (EGFR-λtop) or ERK (RolledSem) results in the differentiation of ectopic veins and wing size reduction, and these phenotypes are stronger in genotypes with maximal overexpression (Figure 6, second and fourth columns). We expect that changes on the level of EGFR or ERK activity, caused by knockdown of other genes, will modify the background phenotype of each individual combination along similar phenotypic series.
Figure 6
Phenotypic series of increased and reduced EGFR signaling in the adult wing. Wings from females grown at 17°C, 25°C, and 29°C (indicated in the left column) of genotypes containing one (salG4) or two [(salG4)x2]) copies of the sal driver in combination with UAS-EGFR-RNAi (EGFR-i column), UAS-EGFR (EGFR-λtop column), UAS-rl-RNAi (rolled-i column), and UAS-rl (rolled-Sem column). Note how the severity of each mutant wing increases (top to bottom) with the level of Gal4/UAS expression.
Phenotypic series of increased and reduced EGFR signaling in the adult wing. Wings from females grown at 17°C, 25°C, and 29°C (indicated in the left column) of genotypes containing one (salG4) or two [(salG4)x2]) copies of the sal driver in combination with UAS-EGFR-RNAi (EGFR-i column), UAS-EGFR (EGFR-λtop column), UAS-rl-RNAi (rolled-i column), and UAS-rl (rolled-Sem column). Note how the severity of each mutant wing increases (top to bottom) with the level of Gal4/UAS expression.
Modifier screen of kinases and phosphatases in EGFR mutant backgrounds
We crossed a collection of UAS-RNAi targeting protein and inositide kinases (211 genes; Supplementary Table S2) and phosphatases (88 genes; Supplementary Table S2) into four different genetic backgrounds with higher (UAS-EGFR-λTop/+; sal/+; Figure 7) or lower (salRNAi/+ Figure 7) than normal EGFR signaling pathway activity. From the resulting phenotypes, we identified those which consistently increased the background wing size and vein differentiation phenotypes (enhancers) and those which reduced these phenotypes (suppressors). In most cases, the expression of UAS-RNAi lines resulted in additive phenotypes (89% for kinases and 91% for phosphatases in average; see Supplementary Table S2). We found modifiers in cases of genes which knockdown have a phenotype by itself (26 genes; Supplementary Table S2) and also for genes which knockdown does not affect wing development (22 genes). In general, the modifiers affected one (11 genes) or more than one background phenotype (24 genes), with cases in which two (6 genes), three (9 cases), or the four (9 cases) backgrounds we used were modified by the knockdown (Supplementary Table S2). Consistently, genes acting as enhancers of EGFR gain of activity conditions usually behave as suppressors of EGFR knockdown conditions and vice versa (Figure 7, A and B). Not unexpectedly, the genes with more hits correspond to core members of the EGFR signaling pathway (Dsor, phl, and rl; Figure 7, B and H–L). Other genes identified as positive regulators because of the opposite effects of their knockdown on the EGFR-λTop and EGFR-RNAi phenotypes, are members of other signaling pathways (babo, Akt1, PI3K92E, and mts), phosphatidylinositol 3-kinases (nonC), cytoplasmic tyrosine kinases (Src42A), and a regulatory subunit of the protein phosphatase 2A (tws; Figure 7B). Similarly, genes identified as negative regulators of EGFR signaling are either components of other signaling pathways (hop, Ptn, csk, wts, Tao, alph, and sgg; Figure 7, B and M–K for the case of sgg), and also include a regulator of clathrin dynamics (aux; Hagedorn ), Casein kinase II β subunit (an enhancer of position effect variegation, see McCracken and Locke 2014) and the phosphatases protein phosphatase 4 regulatory subunit 2-related (PPP4R2r) and Ptp61F (Figure 7B).
Figure 7
Modifications of EGFR and ERK phenotypes by knockdown of kinases and phosphatases. (A) Number of genes that behave as enhancers (E; gray section) or suppressors (R; black section) in the following genetic combination: sal (EGFR-λtop), sal (EGFR-i), sal (rl-Sem), and sal (rl-i). Colored columns represent the number of genes identified as EGFR-λtop enhancers and EGFR-i suppressors (ER; green), EGFR-λtop suppressors and EGFR-i enhancers (RE; blue), rl-Sem enhancers and rl-i suppressors (ER; red) and rl-Sem suppressors and rl-i enhancers (RE; orange). In brackets the number of genes in each class. (B) Genes identified simultaneously in both EGFR and rl screens as positive regulators (green and orange circles, respectively) and as negative regulators (blue and red circles, respectively). (C–G) Control phenotypes used as a background to screen for modifiers UAS-RNAi lines. (H–L) Example of phl, a known member of the EGFR signaling pathway, in the combinations sal (H), sal (I), sal (J), sal (K) and sal (L). (M-Q) Adult wings of combinations involving UAS-sgg-RNAi: sal (M), sal (N), sal (O), sal (P), and sal (Q).
Modifications of EGFR and ERK phenotypes by knockdown of kinases and phosphatases. (A) Number of genes that behave as enhancers (E; gray section) or suppressors (R; black section) in the following genetic combination: sal (EGFR-λtop), sal (EGFR-i), sal (rl-Sem), and sal (rl-i). Colored columns represent the number of genes identified as EGFR-λtop enhancers and EGFR-i suppressors (ER; green), EGFR-λtop suppressors and EGFR-i enhancers (RE; blue), rl-Sem enhancers and rl-i suppressors (ER; red) and rl-Sem suppressors and rl-i enhancers (RE; orange). In brackets the number of genes in each class. (B) Genes identified simultaneously in both EGFR and rl screens as positive regulators (green and orange circles, respectively) and as negative regulators (blue and red circles, respectively). (C–G) Control phenotypes used as a background to screen for modifiers UAS-RNAi lines. (H–L) Example of phl, a known member of the EGFR signaling pathway, in the combinations sal (H), sal (I), sal (J), sal (K) and sal (L). (M-Q) Adult wings of combinations involving UAS-sgg-RNAi: sal (M), sal (N), sal (O), sal (P), and sal (Q).
The components of the InR pathway modify consistently the phenotypes of loss and gain of InR activity
InR signaling is required for wing imaginal cells growth and cell division (Edgar 2006). Consistently, expression of dominant negative or constitutively activated forms of the InR in the wing disc (sal) results in the formation of smaller and larger wings, respectively (Figure 8, A–C). These wings are formed by less and smaller cells (InRDN) or by more and larger cells (InR*; Figure 8D). We used these two genotypes as backgrounds to search for kinases and phosphatases that in knockdown conditions can modify the wing size phenotypes resulting from altered InR signaling. As a preliminary experiment, we tested whether known components of the InR pathway can modify the characteristic InRDN or InR wing phenotypes (Figure 8, E–H). We found that loss of Akt, Pdk1, InR, Tor, and PI3K consistently enhance the wing size and cell size defects caused by InRDN expression (Figure 8G). The same knockdowns also significantly correct the larger than normal wing and cell size caused by expression of activated InR (Figure 8H). The examples of Akt-RNAi and Pdk-RNAi are shown in Figure 8, I–K and M–O, respectively. We also measured wing size for a collection of UAS-RNAi lines corresponding to genes that were identified under the dissecting microscope as “neutral” regarding InRDN or InR effects on wing size. In all cases, we could not find quantitative differences in the size of the corresponding combinations (Figure 8, E and F).
Figure 8
Wing phenotypes resulting from altered levels of InR signaling pathway components. (A–C) Control sal wing (A; orange code) and wings of sal (B; green code), and sal (C; blue code). The change in wing size of combinations involving InR relative to control wings is indicated in the upper-right corner. (D) Quantification of cell size (CELL S) and cell number (CELL NO.) of wings illustrated in (A–C). (E, F) Wing size of ten sal (InRDN; E) and nine sal (InR*; F) combinations that were selected random among those without effects on the InR or InR genetic backgrounds. (G, H) Wing size of six sal (G) and five sal (H) combinations involving known members of the InR pathway (UAS-Akt-RNAi, UAS-PKB-RNAi, UAN-InR-RNAi, UAS-PI3K-RNAi, and UAS-Pten-RNAi). (I) Adult wings of genetic combinations involving UAS-Akt-RNAi combinations: sal (left), sal (middle), and sal (right). (J) UAS-Pdk1 combinations: sal (left), sal (middle), and sal (right). The wing cell size (CELL S) and number (CELL NO.) are shown to the right with the columns in the same color code as the pictures shown in (I) and (J).
Wing phenotypes resulting from altered levels of InR signaling pathway components. (A–C) Control sal wing (A; orange code) and wings of sal (B; green code), and sal (C; blue code). The change in wing size of combinations involving InR relative to control wings is indicated in the upper-right corner. (D) Quantification of cell size (CELL S) and cell number (CELL NO.) of wings illustrated in (A–C). (E, F) Wing size of ten sal (InRDN; E) and nine sal (InR*; F) combinations that were selected random among those without effects on the InR or InR genetic backgrounds. (G, H) Wing size of six sal (G) and five sal (H) combinations involving known members of the InR pathway (UAS-Akt-RNAi, UAS-PKB-RNAi, UAN-InR-RNAi, UAS-PI3K-RNAi, and UAS-Pten-RNAi). (I) Adult wings of genetic combinations involving UAS-Akt-RNAi combinations: sal (left), sal (middle), and sal (right). (J) UAS-Pdk1 combinations: sal (left), sal (middle), and sal (right). The wing cell size (CELL S) and number (CELL NO.) are shown to the right with the columns in the same color code as the pictures shown in (I) and (J).
Modifier screen of kinases and phosphatases in InR mutant backgrounds
We combined the collection of UAS-RNAi lines directed against protein kinases and phosphatases to generate sal flies, and selected those with wing sizes distinct to the corresponding sal background phenotypes. We only found one enhancer of the InRAct phenotype (Tao) and two suppressors of the InRDN phenotype (Csk and Pten). In contrast, we found 30 suppressors of the InRAct phenotype and 34 enhancers of the InRDN phenotype (Figure 9A). Interestingly, 24 of these genes modify the InRAct and InRDN phenotypes in opposite manners, indicating that our screen has the potential to identify genes with a direct connection with Insulin signaling. In fact, we identified as “positive regulators” of InR signaling several known components of the pathway (InR, Tor, Pdk1, Akt1, and PI3K92E; Figures 9B and 10) and Cadherin 96Ca (Cad96Ca), encoding a receptor tyrosine kinase that cooperates with the InR during wing growth (O’Farrell ). Other members of signaling pathways related to growth control identified in the screen were Src42A, ksr, EGFR, rl, and phl (EGFR signaling), the Hippo pathway member Activated Cdc42 kinase (Ack; Hu ), and the TGFβ pathway components punt, babo, and sax (Figure 9B). We also identified as “positive regulators” of InR signaling several Cyclin-dependent kinases (Figures 9B and 10), including Cdk2, regulating G1, and S phases of the cell cycle, Cdk7, a component of the Cdk activating kinase complex with a function in promoting tissue growth through Yorki stabilization (Cho ), Cdk9, involved in RNA polymerase II elongation control (Eissenberg ), and Cdk8, a component of the Mediator complex (Loncle ) that also participates in lipid homeostasis (Zhao ). Other genes related to lipid metabolism were Salt-inducible kinase 2 (Sik2), encoding a serine/threonine kinase that regulates lipid storage and energy homeostasis (Hirabayashi and Cagan 2015), and the regulatory (CkIIβ) and catalytic (CkIIα) subunits of the CKII (Figure 8B). Casein kinase II is a broad specificity Ser-Thr kinase involved in a variety of processes including cell signaling, neuronal physiology, transcription factor activity, and lipid and polyamine metabolism (Stark ; Bandyopadhyay ; McMillan ). Gcn2, related to the regulation of amino acid metabolism (Kang ) and translation initiation (Olsen ) was identified as suppressor of the InRAct large size phenotype (Figure 8B). Other genes identified in the screen as positive regulators of InR signaling encode proteins involved in vesicular trafficking such as fab1 kinase (fab1), encoding a phosphatidylinositol-3-phosphate 5-kinase promoting endosome-to lysosome trafficking (Rusten ), gilgamesh (gish), encoding a plasma membrane-associated kinase regulating Rab11-mediated vesicle trafficking (Gault ) and auxilin (aux), encoding a cofactor for the ATPase Hsc70 that regulates Clathrin dynamics (Kandachar ). Finally, we also identified several genes regulating actin or tubulin dynamics, including microtubule star (mts), encoding the catalytic subunit of protein phosphatase 2A, Protein Kinase D (PKD), and the Phosphatidylinositol 4-Phosphate-5 kinase skittles (Gervais ). Other kinases acting as positive regulators of InR signaling were CG8485 (fly ortholog of human SNF-related kinase), CG8878 (fly ortholog of VRK serine/threonine kinase 3; Figure 9, I–K), CG3277 (fly ortholog of human Colony-stimulating factor 1 receptor), Darkener of apricot (Doa), and minibrain (mnb).
Figure 9
Modifications of InRDN and InRact phenotypes by knockdown of kinases and phosphatases. (A) Number of genes that behave as enhancers (gray section) or suppressors (black section) in the sal (InR*) and sal (InR-DN) genetic backgrounds. The blue column represents the number of genes that were simultaneously identified as suppressors of sal and enhancers of sal (B) Genes identified in both InR screens as enhancers (gray) or suppressors (black). The overlap is colored in blue. (C–E) Control wings of sal (C), sal (D), and sal (E) genotype. (F–H) Example of UAS-PkaC1-RNAi on its own (F) and in combination with UAS-InR (G) and UAS-InR (H). (I–K) Example of UAS-CG8878-RNAi on its own (I) and in combination with UAS-InR (J) and UAS-InR (K).
Figure 10
Numerical analysis of gene knockdowns modifying the wing size of InRDN and InRAct genetic combinations. Percentage of change in wing size, cell size, and estimated cell number (CELL NO.) of mutant combinations between sal (Sal>InR*) or sal (Sal>InRDN) and UAS-RNAi lines of genes modifying the corresponding values of sal (GFP) or sal control flies. Color code indicates the robustness of the change by the significance level.
Modifications of InRDN and InRact phenotypes by knockdown of kinases and phosphatases. (A) Number of genes that behave as enhancers (gray section) or suppressors (black section) in the sal (InR*) and sal (InR-DN) genetic backgrounds. The blue column represents the number of genes that were simultaneously identified as suppressors of sal and enhancers of sal (B) Genes identified in both InR screens as enhancers (gray) or suppressors (black). The overlap is colored in blue. (C–E) Control wings of sal (C), sal (D), and sal (E) genotype. (F–H) Example of UAS-PkaC1-RNAi on its own (F) and in combination with UAS-InR (G) and UAS-InR (H). (I–K) Example of UAS-CG8878-RNAi on its own (I) and in combination with UAS-InR (J) and UAS-InR (K).Numerical analysis of gene knockdowns modifying the wing size of InRDN and InRAct genetic combinations. Percentage of change in wing size, cell size, and estimated cell number (CELL NO.) of mutant combinations between sal (Sal>InR*) or sal (Sal>InRDN) and UAS-RNAi lines of genes modifying the corresponding values of sal (GFP) or sal control flies. Color code indicates the robustness of the change by the significance level.
Concluding remarks
We used the Drosophila wing to identify the in vivo requirements of the Drosophila complement of kinases and phosphatases. Only a low percentage of Carbohydrate, Lipid, and Nucleoside kinases and phosphatases (29%) are required for the correct development of the wing. In contrast a higher percentage of protein kinases, phosphatidylinositol lipid phosphatases, cytoplasmic tyrosine phosphatases, and DSP are required for wing development (45–60% of genes). One caveat of our screen is that we used only one UAS-RNAi line per gene, and this can lead to a wrong estimation of phenotypic frequencies. However, the high coincidence of genes showing a wing phenotype (82%) identified in our screen and in a similar screen in which several independent lines were used suggests that the numbers of false positives and negatives are low. The most frequent phenotypes we observed for these genes were lethality and changes in the size of the wing, associated or not to changes in the position of the veins. These phenotypes are caused by changes in cell division, cell size, and cell viability. We also carried out several modifying screens aiming to identify protein kinases and phosphatases acting as regulators of the EGFR and InR signaling pathways. The correct activation of these pathways is a requisite for the growth and differentiation of the imaginal epithelium, and alterations on the level of their activities led to characteristic adult wing phenotypes that were used as sensitized backgrounds for these screens. We identified modifiers affecting one (11 genes) or more than one (24 genes) EGFR genetic background phenotypes, with genes acting as enhancers of EGFR gain of activity conditions usually behaving as suppressors of EGFR knockdown conditions and vice versa. We also identified a significant group of genes acting as enhancers of InRDN and/or suppressors of InRAct expression. These genes include kinases and phosphatases regulating lipid and amino acid metabolism, cytoskeleton dynamics and vesicle trafficking, other signaling pathways regulating wing growth and several Cyclin-dependent kinases such as Cdk2, Cdk7, Cdk8, and Cdk9 with a variety of functions in cell cycle regulation, tissue growth, RNA polymerase II elongation, and transcription.
Data availability
The data underlying this article are available in the article and in its online supplementary material.Supplementary material is available at G3 online.Click here for additional data file.
Authors: Sergey Apionishev; Natalya M Katanayeva; Steven A Marks; Daniel Kalderon; Andrew Tomlinson Journal: Nat Cell Biol Date: 2004-12-12 Impact factor: 28.824
Authors: Emily A McMillan; Sheila M Longo; Michael D Smith; Sarah Broskin; Baicheng Lin; Nisha K Singh; Todd I Strochlic Journal: J Biol Chem Date: 2018-01-11 Impact factor: 5.157
Authors: Wiljan J A J Hendriks; Ari Elson; Sheila Harroch; Rafael Pulido; Andrew Stoker; Jeroen den Hertog Journal: FEBS J Date: 2012-10-01 Impact factor: 5.542
Authors: Peter Soba; Chun Han; Yi Zheng; Daniel Perea; Irene Miguel-Aliaga; Lily Yeh Jan; Yuh Nung Jan Journal: Elife Date: 2015-03-12 Impact factor: 8.140
Authors: Ana López-Varea; Patricia Vega-Cuesta; Ana Ruiz-Gómez; Cristina M Ostalé; Cristina Molnar; Covadonga F Hevia; Mercedes Martín; Maria F Organista; Jesus de Celis; Joaquín Culí; Nuria Esteban; Jose F de Celis Journal: G3 (Bethesda) Date: 2021-12-08 Impact factor: 3.154